Lychnophora pinaster's effects on inflammation and pain in acute gout

Barros, Camila Helena; Matosinhos, Rafaela Cunha; Bernardes, Ana Catharina Fernandes Pereira Ferreira; Araújo, Marcela Carolina de Paula Michel; Bezerra, Juliana Pantaleão; Sachs, Daniela; Aguiar-Soares, Rodrigo Dian de Oliveira; Saúde-Guimarães, Dênia Antunes

doi:10.1016/j.jep.2021.114460

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 55 ] Pathology shows that TNF is not only the main mediator in the pathogenesis of osteoarthritis, but also an important regulator of inflammatory response and the initiating factor of inflammation, so it can be used as a target for the treatment of gout. [ 56 ] STAT1 is an inflammatory transcription factor, which can inhibit the expression of inflammatory genes by targeting the activation of STAT1. [ 57 ] In general, the results show that DGNTD has multi-target characteristics in the treatment of gout.…”

Section: Discussionmentioning

confidence: 99%

The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout

Liu

Luo

2022

Medicine

View full text Add to dashboard Cite

Background: Due to unhealthy diet and living habits, the incidence of gout is on the rise and has become a common disease with a high incidence. Danggui Niantong decoction (DGNTD), as a classic formula composed of 15 common herbs, has been widely used in clinical practice since ancient times to prevent and treat gout. However, the pharmacological mechanism and target of DGNTD are not clear. Methods: The potential active compounds and targets of DGNTD were obtained by traditional Chinese medicine systems pharmacology (TCMSP) database, and the differential genes of gout patients and controls were analyzed in gene expression omnibus (GEO) database. GSEA analysis of differential genes with GSEA 4.1.0 software and then the differential genes were intersected with the gout-related disease targets searched by GeneCard, CTD and OMIM disease database to obtain the final disease target. The “Traditional Chinese medicine-Active compounds-Targets” network was constructed by Cytoscape3.7.2 software. The R packet is used for enrichment analysis. The molecular docking between the active compound of DGNTD and the core target was verified by AutoDockTools software. Results: Two hundred eighty six and 244 targets of DGNTD-related active components and 652 targets of gout were obtained, of which 13 targets were potential targets of DGNTD in the treatment of gout. GSEA analysis showed that the differential genes were mainly involved in apoptosis, inflammatory reaction, and receptor metabolism and so on. Gene ontology (GO) functional enrichment analysis shows that DGNTD regulates many biological processes, such as the response to purine-containing compound and response to lipopolysaccharide, positive regulation of acute inflammatory response and other cellular components. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis shows that DGNTD treatment of gout is mainly related to interleukin-17 (IL-17), Toll-like receptor, rheumatoid arthritis, tumor necrosis factor (TNF) and so on. The results of molecular docking showed that the five active compounds in DGNTD had strong binding activity to core protein receptors. Conclusions: The active compounds of DGNTD may achieve the purpose of treating gout by acting on the core target (CASP8, CXCL8, FOS, IL1B, IL6, JUN, PTGS2, STAT1, MMP1, TNF) to regulate cell metabolism, proliferation and apoptosis, and improve inflammatory response, which is the result of multi-component, multi-target and multi-pathway interaction. It provides an idea for the development of new combined drugs for gout.

show abstract

Section: Discussionmentioning

confidence: 99%

The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout

Liu

Luo

2022

Medicine

View full text Add to dashboard Cite

show abstract

“…Frontiers in Pharmacology frontiersin.org 08 Compared with CWM alone, the main findings of our metaanalysis show that the combination of DGNT and CWM therapy may be more effective than CWM alone in improving BUA, CRP, ESR, IL-8, Upro, and Scr, which may require more RCT further research. Accumulating studies have shown that BUA, CRP, ESR and IL-8 play an important role in the deterioration of gout (Barros et al, 2021;Calabuig et al, 2021;Deftereos et al, 2022;Kimura et al, 2021;von Groote et al, 2021). Therefore, we reserved the above indicators in the scope of study.…”

Section: Adverse Effectsmentioning

confidence: 99%

Efficacy and safety of Danggui Niantong Decoction in patients with gout: a systematic review and meta-analysis

Peng¹,

Tian²,

Jin³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: This study aims to evaluate the efficacy and safety of Danggui Niantong Decoction (DGNT) systematically on gout treating.Methods: This study was registered in PROSPERO, and the registration number was CRD42021271607. By the end of December, 2022, literature research was conducted among eight electronic databases. Main results of this study were blood uric acid (BUA) and Creactive protein (CRP). Secondary outcomes were erythrocyte sedimentation rate (ESR), serum creatinine (Scr), urinary protein quantified at 24 h (Upro), and interleukin-8 (IL-8). Study screening, data collection, as well as quality assessment were performed by two reviewers independently, and analysis was completed using Stata (SE15.0) and Review Manager (5.4).Results: A total number of 13 studies were included in our meta-analysis (n = 1,094 participants). Results showed DGNT combined with conventional western medicine (CWM) was more effective than WM alone in BUA (weighted mean differences (WMD) = −3.49, 95% confidence interval (CI) [−50.36, −32.59], p = 0.000), CRP (WMD = −41.48, 95% CI [−4.32, −2.66], p = 0.017), ESR (WMD = −6.23, 95% CI [−9.28, −3.17], p = 0.019), Scr (WMD = −18.64, 95% CI [−23.09, −14.19], p = 0.001), Upro (WMD = −0.72, 95% CI [−0.91, −0.53], p = 0.000), and IL-8 (WMD = −4.77, 95% CI [−11.48, 1.94], p = 0.000). None of the adverse effects noted were severe, and no life-threatening event was reported.Conclusion: This study shows that DGNT combined with CWM seems to have an effective clinical therapeutic potential. In addition, it also provides a scientific basis for better clinical application of DGNT in the future.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021271607; Identifier: PROSPERO, CRD42021271607.

show abstract

“…The long-term high concentration of serum uric acid leads to the crystallization of uric acid in joints and soft tissues in the body, causing damage to connective tissues and triggering gout [3,4]. In acute gouty arthritis, the interaction between urate crystals and phagocytes (such as macrophages and infiltrating white blood cells) induces the secretion of various inflammatory mediators, including cytokines, chemokines, and interleukin, triggering typical inflammatory reactions [5,6]. Therefore, the usual means of treating gout aim to inhibit the production of uric acid and promote the excretion of uric acid.…”

Section: Introductionmentioning

confidence: 99%

Mining Xanthine Oxidase Inhibitors from an Edible Seaweed Pterocladiella capillacea by Using In Vitro Bioassays, Affinity Ultrafiltration LC-MS/MS, Metabolomics Tools, and In Silico Prediction

Wang,

Zhou,

Chen

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

The prevalence of gout and the adverse effects of current synthetic anti-gout drugs call for new natural and effective xanthine oxidase (XOD) inhibitors to target this disease. Based on our previous finding that an edible seaweed Pterocladiella capillacea extract inhibits XOD, XOD-inhibitory and anti-inflammatory activities were used to evaluate the anti-gout potential of different P. capillacea extract fractions. Through affinity ultrafiltration coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS), feature-based molecular networking (FBMN), and database mining of multiple natural products, the extract’s bioactive components were traced and annotated. Through molecular docking and ADMET analysis, the possibility and drug-likeness of the annotated XOD inhibitors were predicted. The results showed that fractions F4, F6, F4-2, and F4-3 exhibited strong XOD inhibition activity, among which F4-3 reached an inhibition ratio of 77.96% ± 4.91% to XOD at a concentration of 0.14 mg/mL. In addition, the P. capillacea extract and fractions also displayed anti-inflammatory activity. Affinity ultrafiltration LC-MS/MS analysis and molecular networking showed that out of the 20 annotated compounds, 8 compounds have been previously directly or indirectly reported from seaweeds, and 4 compounds have been reported to exhibit anti-gout activity. Molecular docking and ADMET showed that six seaweed-derived compounds can dock with the XOD activity pocket and follow the Lipinski drug-like rule. These results support the value of further investigating P. capillacea as part of the development of anti-gout drugs or related functional foods.

show abstract

Lychnophora pinaster's effects on inflammation and pain in acute gout

Cited by 7 publications

References 29 publications

The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout

The combination of molecular docking and network pharmacology reveals the molecular mechanism of Danggui Niantong decoction in treating gout

Efficacy and safety of Danggui Niantong Decoction in patients with gout: a systematic review and meta-analysis

Mining Xanthine Oxidase Inhibitors from an Edible Seaweed Pterocladiella capillacea by Using In Vitro Bioassays, Affinity Ultrafiltration LC-MS/MS, Metabolomics Tools, and In Silico Prediction

Contact Info

Product

Resources

About